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Previous reports from the Tuberculosis Chemotherapy Centre, Madras, have described
a comparison of four regimens (three of isoniazid alone and one of isoniazid plus PAS)
in the treatment of pulmonary tuberculosis and an investigation of the serum isoniazid
levels in the patients concerned. The present report studies the emergence of isoniazid-
resistant organisms in these patients during treatment. All patients with an unsatisfactory
response to treatment yielded resistant cultures, showing that the isoniazid dosage was
never too low to inhibit sensitive organisms. From the degree of resistance of the first
resistant cultures and of the six-month cultures from the patients treated with isoniazid
alone it was concluded that resistance emerged in two stages. In the first stage, very early in
treatment, highly resistant mutant bacilli grew freely whatever the isoniazid dosage, but
mutants of lower resistance were prevented from growing to an extent dependent on the peak
isoniazid concentration in the serum. Consequently, when the isoniazid dosage was increased
the proportion of patients with resistant organisms decreased, since fewer low-resistance
strains were able to develop. In the second stage, organisms with relatively low resistance
continued to multiply, though still partially inhibited by isoniazid, and became more
resistant, particularly in slow inactivators. The first-stage events determined the results
of treatment since, once resistance had emerged, its extent was unrelated to the patient’s
eventual progress. These findings emphasize the importance of early intensive chemotherapy
and adjustment of the isoniazid dosage according to peak serum concentrations rather
than concentrations measured three or six hours after the dose. Concomitant adminis-
tration of PAS prevented emergence of isoniazid resistance in many patients and in others
delayed its emergence and reduced its degree, possibly because growth in the secondstage
was slow.
INTRODUCTION
A previous report from the Centre (Tuberculosis
Chemotherapy Centre, 1960) presented the results
of a controlled comparison of isoniazid plus
p-aminosalicylic acid (PAS) with three regimens of
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isoniazid alone in the domiciliary treatment of
pulmonary tuberculosis in South India. In terms
of the attainment of bacteriologically quiescent
disease by 12 months, the regimen of isoniazid plus
PAS was the most effective, a moderate dosage of
isoniazid (approximately, 8.7 mg/kg body-weight)
given alone in one dose a day was less effective
and the same moderate daily dosage and a low
daily dosage (on the average, 4.5 mg/kg) both given
alone in two doses a day were least effective. There
was also a suggestion in all four treatment series
that the slow inactivators of isoniazid responded to
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treatment slightly better than the rapid inactivators
(Selkon et al., 1961).
With the exception of a few patients who died or
had their chemotherapy changed in the early months,
failure to respond to treatment was always accompa-
nied by the emergence of isoniazid-resistant tubercle
bacilli. An attempt has therefore been made in
the present report to investigate whether differences
in the progress of the patients receiving the various
regimens of treatment could be explained in terms
of the degree of resistance of the resistant organisms.
In the patients who were treated with isoniazid
alone, an increase in the dosage has been shown to
lead to the attainment of higher serum concentra-
tions of isoniazid (Gangadharam et al., 1961b),
and it is possible that these higher serum concentra-
tions might have prevented the growth of organisms
with low degrees of resistance, thus decreasing the
chance of resistant bacilli appearing in the sputum.
Further, the concomitant administration of PAS
might have either delayed or prevented the emergence
of isoniazid-resistance. These possibilities have been
examined by considering the degree of resistance and
the month of emergence of isoniazid-resistant strains
in the slow and rapid inactivators in the four treat-
ment series. Further papers will describe certain
other characteristics of the resistant strains, parti-
cularly their virulence in the guinea-pig, and the
elimination of sensitive organisms during treatment,
since these factors might also have influenced the
response of the patients to treatment.
MATERIALS AND METHODS
PATIENTS
In all, 341 patients aged 12 years or more with
newly diagnosed, culture-positive, pulmonary tuber-
culosis were allocated at random to treatment with
one of four regimens of chemotherapy for 12 months
(Tuberculosis Chemotherapy Centre, 1960). The
four regimens studied were:
PH (96 patients)
Isoniazid 3.9-5.5 mg/kg body-weight plus sodium
PAS 0.2-0.3 g/kg daily, divided into two doses,
by mouth–i.e., 200 mg of isoniazid plus 10 g of
sodium PAS a day for a patient weighing 100 lb
(45.4 kg).
HI-1 (75 patients)
Isoniazid alone, 7.8-9.6 mg/kg daily in one dose,
by mouth–i.e., 400 mg of isoniazid a day for a
patient weighing 100 lb.
HI-2 (75 patients)
Isoniazid alone, 7.8-9.6 mg/kg daily, divided into
two doses, by mouth,–i.e., 400 mg of isoniazid
a day for a patient weighing 100 lb.
H (95 patients)
Isoniazid alone, 3.9-5.5 mg/kg daily divided into
two doses, by mouth–i.e., 200 mg a day for a
patient weighing 100 lb.
The size of the dose prescribed was related to the
patient’s weight. It will be appreciated that the size
of the average single dose of the HI-1 regimen was
twice that of the HI-2 regimen which was, in turn,
twice that of the H regimen.
The patients received the allocated chemotherapy
for 12 months (and in some instances for 24 months)
unless it was changed on account of clear-cut
radiographic extension of the disease confirmed by
an independent assessor, serious clinical deterioration
or peripheral neuropathy. The management of the
patients has been described in detail elsewhere
(Tuberculosis Chemotherapy Centre, 1960).
For reasons given in the earlier report (Tubercu-
losis Chemotherapy Centre, 1960) 26 of the
341 patients were excluded from the main analysis,
22 because they had isoniazid-resistant cultures on
admission. A further 10 patients (five PH, one HI-1,
one HI-2, three H) are excluded from the present
analysis. Three patients died from tuberculosis and
two more had their treatment changed on account
of drug-toxicity, all during the first three months
while they were still excreting isoniazid-sensitive
organisms. The other five died from non-tuberculous
causes during the year. There remained 305 patients
(85 PH, 69 HI-1, 67 HI-2, 84 H) all of whom had
isoniazid-sensitive cultures on admission to treatment
and had previously received, at the most, two weeks
of antituberculosis chemotherapy (the great majority
had received none).
ASSESSMENTS ON THE PATIENTS
Full details of the assessments made on the
patients on admission and during their treatment
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have been given in the main report on the study
(Tuberculosis Chemotherapy Centre, 1960). The
more important of these, which have been used in
the present report, are as follows.
On the patient’s admission to the study, the
severity of the disease was assessed in terms of the
extent of cavitation and the total extent of disease
read from a full-plate postero-anterior radiograph
by an independent observer (Dr Raj Narain). In
addition, a smear prepared from a sputum specimen
that had been collected overnight was graded for
its bacterial content, using fluorescence microscopy.
The progress of the patients during treatment was
classified according to the bacteriological status of
their disease at 12 months. At the end of each
month of treatment, two specimens of sputum and,
from the third month onwards, a pair of laryngeal
swabs from each patient were cultured. A patient
was considered to have quiescent disease (and a
favourable response) at 12 months if all of the
specimens taken at 10, 11 and 12 months were
negative on culture (seven to nine culture results
were usually available during this period). Included
in this category, in the present report, are also those
few patients who, following at least three months
of culture negativity, yielded a single positive
culture at 10, 11 or 12 months, since their subsequent
progress was similar (Velu et al., 1961). The
remaining patients with an unfavourable response
were bacteriologically active at 12 months, or at
the time that their treatment was changed because
of radiographic or clinical deterioration, or when
they died. Of the six patients who had their treatment
changed because of the occurrence of peripheral
neuritis, one has been regarded as having quiescent
disease and five as having active disease at 12 months,
for reasons given by Selkon et al. (1961).
CULTURE AND ISONIAZID SENSITIVITY TESTS
Sputum specimens, after treatment with 4%
sodium hydroxide, and laryngeal swabs, after
treatment with 4% sulfuric acid, were cultured on
Löwenstein-Jensen medium without potato starch
by methods previously described (Tuberculosis
Chemotherapy Centre, 1959). Usually within three
days of the culture becoming positive, sensitivity
tests to isoniazid were set up on two pretreatment
cultures and on one culture obtained from each
patient at the end of each month of treatment.
The inoculum suspension was made by adding, as
judged by eye, approximately 2 mg (moist weight)
of bacilli, obtained as a representative sample of
the growth on the Löwenstein-Jensen medium slope,
to ¼-ounce (7-ml) screw-capped bottles containing
0.5 ml of sterile distilled water and six glass beads.
After the bottle had been shaken mechanically for
one minute, a 3-mm loopful of this suspension
(containing about 105 viable units) was inoculated
on to each of a series of slopes of Löwenstein-
Jensen medium containing 0.2, 1, 5 and 50 µg/ml
isoniazid, and on a drug-free slope as a control.
The standard sensitive strain of Mycobacterium
tuberculosis, H37Rv, was also set up with each
series of tests, on a drug-free slope and on slopes
containing 0.025, 0.05, 0.1, 0.2 and 1 µg/ml isoniazid.
The tests were read after four weeks incubation
at 37°C; they were repeated on the rare occasions
when the drug-free slope yielded 100 or fewer
colonies. The minimal inhibitory concentration
(MIC) was defined as the lowest concentration of
isoniazid on which less than 20 colonies grew.
Cultures isolated during treatment which had MICs
of 0.2 µg/ml were regarded as sensitive, and those
with MICs of 1 µg/ml or more as resistant. An
MIC of 1 µg/ml was regarded as a low degree of
resistance, 5 µg/ml as moderate resistance, 50 µg/ml
as high resistance and greater than 50 µg/ml as very
high resistance to isoniazid.
RATE OF INACTIVATION OF ISONIAZID
The rate of inactivation of isoniazid was deter-
mined by microbiological assay of the isoniazid
present in the serum four-and-a-half hours after a
test dose of 3 mg of isoniazid per kg body-weight,
given intramuscularly (Gangadharam et al., 1961a).
Patients with serum concentrations of 0.58 µg/ml
or more isoniazid were classified as slow inactivators
and those with concentrations of less than 0.58 µg/ml
isoniazid as rapid inactivators. The rate of inactiva-
tion of isoniazid was determined in 299 of the
305 patients; in two patients (one PH, one HI-1)
the tests were contaminated; in one patient (PH)
the blood was collected half-an-hour too late, and
three patients (one HI-2, two H) died before the
test was done.
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RESULTS
The results are presented in four sections. In
the first the variation encountered in the isoniazid-
sensitivity tests is considered. The second presents
the pattern of emergence of resistance and studies
the influence of two background factors, the speed
of emergence of resistance and the condition of
the patient’s disease on admission to treatment, on
the degree of resistance. The third section de-
scribes the proportions of patients in the four treat-
ment series, considered separately as slow or rapid
inactivators, who yielded resistant cultures and the
degree of resistance of these cultures. In the fourth
section the response to treatment of those patients
who yielded isoniazid-resistant cultures during the
year was studied in relation to the degree of the
resistance of their cultures.
VARIATION IN RESULTS OF
ISONIAZID-SENSITIVITY TESTS
Variation between duplicate tests on the same culture
The reproducibility of the isoniazid-sensitivity
test was studied by comparing the results of duplicate
tests set up on 63 cultures, five obtained from
patients in the study before the start of treatment
and the remainder between five months and
24 months, while the patients were still receiving
their initially allocated chemotherapy. The duplicate
tests were set up from the same culture within a
few days of each other by separate workers, who
were unaware of the purpose of the investigation,
and were read independently.
The results of the duplicate tests are summarized
in the first line of Table 1. Of the 63 cultures,
10 were sensitive, having an MIC of 0.2 µg/ml or
less in the first test, 10 had an MIC of 1 µg/ml,
15 had an MIC of 5 µg/ml, 13 had an MIC of
50 µg/ml and 15 had an MIC of more than 50 µg/ml.
In the second test, 56 had the same MIC and the
remaining seven had MICs which were only one
dilution step different; four were less resistant and
three were more resistant. None of the cultures
yielded a resistant result (MIC of 1 µg/ml or more)
in one test and a sensitive result (MIC of 0.2 µg/ml)
in the other test.
Variation in degree of resistance of six- and seven-
month cultures isolated from the same patient
The variation inherent in the sampling of the
bacterial populations in the lesions of patients was
investigated by comparing the results on different
sputum specimens from the same patient. The
tests on cultures isolated at six and seven months
were chosen for this comparison since only one
positive culture isolated at each month was tested
for its sensitivity and since the results on six-month
cultures have been used in the following sections of
the report. The results obtained on the six-month
and seven-month cultures that were isolated from
each of 66 patients who had sensitivity test results
on cultures obtained at both of these months are
summarized in the second line of Table 1. All of
the 132 cultures tested were resistant to isoniazid.
In 58 of the 66 patients the six- and seven-month
TABLE 1
COMPARISON OF THE PO-COLONY AND EQUAL-GROWTH END-POINTS IN DUPLICATE ISONIAZID SENSITIVITY TESTS
AND IN SENSITIVITY TESTS ON SIX-MONTH AND SEVEN-MONTH CULTURES ISOLATED FROM THE SAME PATIENT
Comparison of the results in the 2 sensitivity tests
Comparison Total
MIC in first test or in test on six-month
culture higher
MIC in first test or in test on
cultures six-month culture lower
(No. of dilution steps a) (No. of dilution steps a)
Between duplicate sensitivity on
tests on same culture
Between six-month and seven-
month cultures from same patient 66 0 1 0 0 58 6 0 1
a The isoniazid concentrations in the tests were 0.2, 1, 5 and 50 µg/ml.
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cultures had the same MIC. The seven-month
culture had an MIC which was one dilution step
higher than the six-month culture in six patients,
and an MIC three dilution steps higher in one
patient. In one patient the seven-month MIC was
three dilution steps lower than the six-month MIC.
Consistency of resistance in multiple cultures from
the same patient
The consistency with which cultures, once resistant,
were succeeded by further resistant cultures from the
same patients was also examined. Of the 305 patients
in this study, 120, after yielding a resistant culture,
had an isoniazid-sensitivity test result on at least
one subsequent culture. From these 120 patients,
703 cultures, which were tested for their sensitivity
to isoniazid, were isolated after the emergence of the
first isoniazid-resistant culture until the end of the
year of treatment or until the month in which their
treatment was changed. Of the 703 cultures, only
11 (1.6 %) were sensitive to isoniazid.
EMERGENCE OF ISONIAZID-RESISTANT CULTURES
DURING TREATMENT
Response of the patients to treatment related to the
emergence of resistance
Of the 305 patients in the study, 136 yielded one
or more isoniazid-resistant cultures during the first
year while receiving their allocated treatment. These
136 patients included all of the 103 patients whose
disease failed to become bacteriologically quiescent
at 12 months. The proportion of cultures that were
resistant to isoniazid at each month of treatment
increased during the first five months and, at six
months, 97 % of the 90 cultures were resistant. In the
second six months, only nine of the 415 cultures
tested were sensitive; these were obtained from eight
patients (one H, three HI-2, two HI-1, two PH).
Of the eight patients, seven (two slow inactivators,
five rapid inactivators) attained quiescent disease;
one (slow inactivator) yielded a resistant culture at
11 months and, since two positive cultures had been
obtained in the last three months of treatment,
was classified as having active disease. Thus, an
unfavourable response was invariably accompanied
by the emergence of resistance and there was no
evidence of the persistent excretion of isoniazid-
sensitive organisms, even in rapid inactivators
receiving a low dosage of isoniazid. The isolation on
culture of isoniazid-sensitive organisms in the
second six months was a rare phenomenon and did
not presage a failure to attain quiescent disease at
12 months.
Proportions of patients with resistant cultures
One or more isoniazid resistant cultures were
obtained from 57 (68%) of the 84 H patients,
33 (49%) of the 67 HI-2 patients, 30 (43%) of the
69 HI-1 patients and from 16 (19 %) of the 85 PH
patients. Thus, in the isoniazid-alone series, the
proportion of patients with resistant cultures was
highest in the H series and lowest in the HI-1 series.
Considerably fewer of the PH patients yielded
resistant cultures than did the patients treated with
isoniazid alone.
Speed of emergence of resistant cultures
The month of treatment at which the first (or
only) resistant culture was isolated from the slow
and rapid inactivators of isoniazid in the four
treatment series is set out in Table 2. The first
resistant culture was obtained at one to four months
from 75 % of the 57 H patients who yielded resistant
cultures, from 85% of the 33 HI-2 patients, from
83 % of the 30 HI-1 patients and from only 25 % of
the 16 PH patients. Thus, the majority of the resis-
tant cultures were obtained during the first four
months in the patients treated with isoniazid alone,
but the emergence of resistance was delayed in the
PH series. The speed of emergence of resistance was
similar in the three isoniazid-alone series, the
proportions of resistant cultures obtained for the
first time at one or two months being 56% in
the H series, 55 % in the HI-2 series and 60 % in the
HI-1 series. First resistant cultures emerged at
about the same time in the slow and rapid inactiva-
tors in each of the treatment series.
Degree of resistance of the first resistant cultures
The degree of resistance of the first resistant
cultures, and the month of treatment in which they
were obtained, are set out in Table 3. First resistant
cultures with MICs of 1 µg/ml were obtained from
21% of 100 patients in the first four months of
treatment and from 31% of 36 patients in the
remaining eight months. Thus, the degree of
resistance of the first resistant cultures was not
related to the duration of treatment before their
emergence.
Effect of continued treatment on the degree of
resistance
The effect of continued treatment on the degree
of resistance to isoniazid is shown in the accompa-
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TABLE 2
MONTH OF EMERGENCE OF THE FIRST ISONIAZID-RESISTANT CULTURE IN SLOW AND RAPID
INACTIVATORS OF ISONIAZID IN THE FOUR TREATMENT SERIES
Treatment
series
Rate of
Inactivation
of isoniazid
Month of emergence of the first resistant culture
Total patients
who yielded
resistant
cultures
PH
HI-1
HI-2
H
All patients 57c 32c 56 1 1 19 10 18 4 7
a The parentheses Indicate percentages based on fewer than 25 observations.
b Indicates the inclusion of one patient whose rate of inactivation was not determined.
c Indicates the inclusion of two patients whose rate of inactivation was not determined.
nying figure. The proportion of cultures with MICs of the first resistant culture. MICs of 1 µg/ml were
of 1 µg/ml decreased from 24% of 25 resistant obtained with 23 % of the 136 first resistant cultures,
cultures at one month, to 16% of 87 at six months, with 16% of the 94 resistant cultures at the first
and to 7% of 72 at nine months. Thereafter, it subsequent month, with 11 % of the 101 resistant
remained fairly constant and was 8% of 52 at cultures at the second subsequent month, with
12 months. The proportion of cultures with MICs 6 % of the 64 resistant cultures at the sixth subsequent
of 5 µg/ml and 50 µg/ml remained fairly constant month and with 3% of the 38 resistant cultures at
over the year. The proportion of cultures with the tenth and eleventh subsequent months. Thus,
MICs of greater than 50 µg/ml increased from the tendency for the degree of resistance to increase
20 % of 25 at one month to 26 % of 87 at six months, during treatment was at least as evident in successive
to 39% of 72 at nine months and to 40% of 52 cultures from the same patient as in successive
at 12 months. This increase in the degree of resistance months of treatment. The increase in the degree
during treatment was shown by both the slow and of resistance was also more evident in the earlier
the rapid inactivators of isoniazid. than in the later resistant cultures.
The degree of resistance of successive resistant
cultures from the same patient was also studied by
amalgamating all first resistant cultures, and,
correspondingly, all resistant cultures obtained
thereafter at each month subsequent to the isolation
In order to avoid bias in the above analysis, the
data were examined further (but are not tabulated
here) to see whether changes in the degree of
resistance were similar in patients who had few or
many resistant cultures during the year of treatment
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TABLE 3
DEGREE OF RESISTANCE TO ISONIAZID OF FIRST RESISTANT CULTURE RELATED TO
THE MONTH OF EMERGENCE
Month of
treatment
Total Minimal inhibitory concentration of isoniazid (µg/ml)
cultures
1 5 50 >50
No. % No. % No. % No. % No. %
1-4 100 100 21 21 35 35 25 25 19 19
5-8
136
100 8 27 7 23 5 17 10 33
9-12 100 3 (50)a 2 (33) 0 (0) 1 (17)
Total 100 32 24 44 32 30 22 30 22
a The parentheses indicate percentages based on fewer than 25 observations.
and whether the patients who became bacterio-
logically negative or who changed treatment, and
were therefore lost from the population studied,
differed from the remaining patients in the degree
of resistance of their cultures. No reason was found
to alter the conclusion that the degree of resistance
in the individual patient increased as treatment was
continued.
Influence of the pretreatment condition of the disease
on the emergence of resistance
The relationship between the pretreatment condi-
tion of the disease and the emergence of resistance
has been studied in the first isoniazid-resistant culture
obtained from each patient and in a population of
resistant cultures termed the “ supplemented six-
month ” cultures. The first isoniazid-resistant
cultures were chosen for study since they were the
cultures that most closely represented the types of
resistant mutant that originally emerged from the
patient’s population of sensitive bacilli. The sup-
plemented six-month cultures consisted of a single
culture obtained from each patient at six months,
provided that this culture was available and resistant.
If the six-month culture was negative or con-
taminated, the resistant culture isolated at seven or at
five months was included, in this order of preference.
The five-month resistant culture from four patients
who had their treatment changed during the sixth
month was also included. Cultures from seven
THE DEGREE OF RESISTANCE OF.
ISONIAZID-RESISTANT CULTURES
OBTAINED DURING THE YEAR OF TREAT-
MENT (COMBINED RESULTS IN ALL FOUR
TREATMENT SERIES)
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patients (three H, two HI-2, two HI-1) who had
their treatment changed or died before completing
five months of treatment were excluded. The
supplemented six-month cultures were chosen for
study because an appreciable number of patients
had their treatment changed during the following
few months.
Table 4 relates the pretreatment condition of the
disease to the proportion of patients who yielded
resistant cultures and to the degree of resistance both
for the first and for the supplemented six-month
resistant cultures. The four treatment series are
not presented separately since analyses (not tabulated
here) showed that they were similar in respect of
the associations considered below.
Proportion of patients with resistant cultures. As
can be seen from the first two columns of Table 4,
one or more resistant cultures were obtained
from 99 (52%) of 191 patients with extensive or
moderate cavitation on admission, but from only 37
(32 %) of 114 patients with slight or no cavitation,
a highly significant difference (P<0.001). Patients
with gross or extensive disease also yielded resistant
cultures more often than those with less extensive
disease. Considering the bacterial content of single
pretreatment collection specimens, resistant cultures
were obtained from 52% of 201 patients with
3-plus or 2-plus smear gradings and from 31% of
104 patients with I-plus or negative smears; this
difference is highly significant (P<0.001). In a
similar manner a higher proportion of patients with
initially more severe disease yielded supplemented
six-month resistant cultures.
Degree of resistance. Table 4 also relates the
degree of resistance of the first resistant cultures to
the condition of the patients on admission to
treatment. Cultures with MICs of 1 µg/ml were
obtained from 20% of the 99 patients with resistant
cultures who had moderate or extensive cavitation
and from 30% of 37 with slight or no cavitation.
The corresponding proportions were 25% for the
48 patients who had gross or extensive disease on
admission, as compared with 22 % for the 88 patients
who had moderate or less disease, and 23% for
the 104 patients who had 3-plus or 2-plus positive
smears as compared with 22% for the 32 patients
who had l-plus positive or negative smears. An
absence of association between the degree of
resistance and the pretreatment severity of the
disease was also noted with the supplemented
six-month cultures (Table 4).
In summary, there was an association between
the proportion of patients who yielded one or more
isoniazid-resistant cultures during treatment and
the extent of cavitation, the total extent of disease
and the degree of sputum positivity on admission to
treatment. On the other hand there was no evidence
that, in the patients who yielded resistant cultures,
the degree of resistance of either the first or the
supplemented six-month cultures was related to the
initial condition of the patients on admission to
treatment.
COMPARISON OF THE DEGREE OF RESISTANCE OF
ISONIAZID-RESISTANT CULTURES IN THE
FOUR TREATMENT SERIES
This section compares the emergence of isoniazid-
resistance in the four treatment series and in the
slow and rapid inactivators of isoniazid. The
purpose of this comparison was to determine
whether the dosage of isoniazid and the differences
in the serum levels of isoniazid attained by slow
and rapid inactivators (Gangadharam et al., 1961b)
were related to the frequency of emergence of
resistant cultures and to the degree of their resistance.
For simplicity of presentation, only the first and
the supplemented six-month resistant cultures (for
definition see page 279) are considered here.
First resistant cultures
In Table 5 are set out the numbers of patients
who yielded one or more isoniazid-resistant cultures
during the year, the degree of resistance of the
first resistant cultures and the bacteriological status
at one year of the patients in the four treatment
series. The eight subgroups, formed by the slow
and rapid inactivators in the four treatment series,
are arranged in order of the response to treatment
that was obtained (Table 5, last column). Thus,
the H regimen in rapid inactivators was the least
effective and the PH regimen in slow inactivators
was the most effective. The proportion of patients
who yielded isoniazid-resistant cultures in each of
the subgroups decreases in the same order, from
69 % of the 36 H rapid inactivators to 14% of the
57 PH slow inactivators.
Among the patients who received isoniazid alone,
cultures with MICs of 1 or 5 µg/ml were obtained
from 44% of the 36 rapid inactivators in the
H series, from 35% of the 46 slow inactivators in
the H series, from 26% of the 27 rapid inactivators
TABLE 4
DEGREE OF RESISTANCE TO ISONIAZID OF THE RESISTANT CULTURES ISOLATED DURING TREATMENT
RELATED TO THE CONDITION OF THE DISEASE ON ADMISSION TO TREATMENT
First isoniazid-resistant culture I Supplemented six-month isoniazid-resistant culture
I I Patients
Pretreatment
assessments
Total
with
resistant
e~~tf$er-d  cultures (k
Cd
No. % Oi
b-4
Ex2nt
cavi-
tation
Extensive
or moderate
Slight
Nil
Gross or
extensive I 88 I 48 55
Total
extent Moderate or
of limited
disease
Slight or
trivial i 26 I 5 19
3-plus I 111 I 66 59
sputum
positivity
d%ct
smear
) )49)1327Negative
-
I
Total patients ( (136 45305
I
-
-
I-
-
I-
1
Minimal inhibitory concentration
of isoniazid (pa/ml)
Pa;;;ts Minimal inhibitory concentration
T o t a l
of isoniazid (tig/ml)
5 50 >50 e~~ti$,tesd  cultures (d)
N o .  ybrf N o .  7b;f  N o .  ybyf
w
;;icif No.  ‘.?fGf  j No.  ‘?jGf 1 No;& 1 yb;’
20 20
8 27
3 (43)
12 25
17 20
2 (43)
16 24
6 27
2 (17)
5 (38)
31 23
34 34 1 24 24 1 21 27 1 185 1 80 43 1 12 15 i 28 35 j 19 24 i 21 26
IO 33 / 4 13 j 8 27 / 91 / 23 25 1 4 (,7)nl 6 (26) 1 6 (26) / 7 (30)
2 (29) j 1 (14) / 1 (14) / 22 1 6 (27) j 2 (33) / 1 (17) / 1 (17) 1 2 (33)
18 33 1 10 21 1 8 17 / 84 1 38 45 1 7 18 1 11 29 / I I 29 1 9 24
25 3. 1 19 23 i 22 27 / 189 j 67 35 / 9 73 1 22 33 1 15 22 / 21 31
3 (50) 1 0 (0) j 0 (0) 1 25 / 4 16 / 2 (50)  / 2 (50) 1 0 (0) / 0 (0)
24 36 / 12 78 / 14 27 ( 108 1 53 49 1 9 17 j 20 38 i I I 21 / 13 P5
IO 26 1 I I 29 / 9 24 / 86 1 32 36 / 6 19 / 8 25 1 9 28 / 9 28
7 (37) ( 4 (27) j 6 (32) ( 53 1 17 32 1 1 (6) / 4 (24) 1 4 (24) / 8 (47)
5 (38) ) 2 (15) j 1 (8) j 49 1 7 14 1 2 (29) / 3 (43) j 2 (29) 1 0 (0)
46 34 1 29 21 / 30 21 / 2986 109 37 18 17 35 32 26 24 30 28
e The parentheses indicate percentages based on fewer than 25 observations.
b Excluding seven patients who had died or had their treatment changed before completing five  months of treatment,
TABLE 5
DEGREE OF RESISTANCE TO ISONIAZID OF THE FIRST RESISTANT CULTURES FROM PATIENTS IN THE FOUR TREATMENT SERIES
HI-1
HI-2
H
Al l
isoniazid-
alone
series
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
57
26
85 a
36
32
69 b
39
27
67 b
46
36
84 a
121
95
220
Total patients Minimal inhibitory concentration of isoniazid (µg/ml) Patients with
with first isoniazid- bacteriologically
resistant cultures quiescent disease
1  5 
No. % of (a) No. % of (a) No. % of (a)
8 14 3 5 3 5
5 19 3 12
16 19 8 9 6 7
1 3 9 25
2 6 4 12
3 4 13 19
1 3 5 13
4 15 3 11
5 7 9 b 13
30 65 4 9 12 26
10 28 6 17
57 a 68 15b 18 18 21
6 5 26 21
16 16 13 14
120 54 23 10 40 18
50
No. % of (a)
1 2
0 0
1 1
4 11
2 6
6 9
6 15
3 11
9 13
7 15
5 14
13b 15
17 14
10 10
28 13
>50 at one year
No. % of (a) No. % of (a)
1 2 54 95
0 0 22 85
1 1 78 a 92
2 6 26 72
6 19 21 66
8 12 48b 70
6 15 23 59
4 15 15 56
10 15 38 57
7 15 22 48
4 11 16 44
11 13 38 46
15 12 71 59
14 15 52 55
29 13 124 56
a lndicates the inclusion of two patients whose rate of inactivation of isoniazid was not determined.
b Indicates the inclusion of one patient whose rate of inactivation of isoniazid was not determined.
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in the HI-2 series and from 20% of the remaining
108 patients in the HI-2 and HI-1 series. On the
other hand, the proportions of patients with cultures
that had MICs of 50 µg/ml or more are similar in
each of the subgroups. Thus, it appears that the
decrease in the proportion of patients with resistant
strains, from the rapid inactivators of the H series
to the slow inactivators of the HI-1 series, is mainly
due to a deficiency of patients with cultures of low
or moderate degrees of resistance. This conclusion,
though uncertain for the data for the HI-1 series
and for the HI-2 slow inactivators, is supported by
the tidings on the supplemented six-month cultures
presented below.
Among the cultures with low or moderate degrees
of resistance, a further association is evident between
the degree of resistance and the rate of inactivation
of isoniazid, such that the proportion of cultures
with low degrees of resistance is higher in the rapid
inactivators than in the slow inactivators. Thus,
among those patients in the H series who had
cultures with MICs of 1 or 5 µg/ml, only four of
16 cultures from slow inactivators had cultures with
an MIC of 1 µg/ml, as compared with 10 of the
16 corresponding cultures from rapid inactivators.
Similar findings are also evident in the remaining
two series. Amalgamating the results in the three
isoniazid-alone series, an MIC of 1 µg/ml was
obtained with six (19%) of the 32 cultures with
MICs of 1 or 5 µg/ml from slow inactivators and
from 16 (55 %) of the 29 corresponding cultures
from rapid inactivators, a significant difference
(P<0.01).
A comparison of the degree of resistance of
cultures from patients in the PH and the HI-2 series
is of interest, since the patients on these two regimens
had similar serum concentrations of isoniazid
(Gangadharam et al., 1961b). Cultures with MICs
of 50 µg/ml or more were obtained from 2% of
the 85 PH patients, but from 28% of the 67 HI-2
patients, a highly significant difference (P<0.001).
The proportions of cultures with MICs of 1 or
5 µg/ml were, however, similar in the PH series
(16 % of 85 patients) and in the HI-2 series (21% of
67 patients). Thus, the concomitant administration
of PAS with isoniazid resulted in a considerable
decrease in the proportion of patients who yielded
cultures with high or very high degrees of resistance.
Supplemented six-month resistant cultures
The degree of resistance of the supplemented
six-month resistant cultures from the slow and
rapid inactivators in the four treatment series is
set out in Table 6, also arranged in order of efficacy
of the regimens. These cultures were usually
obtained after the first resistant cultures when the
degree of resistance had increased slightly. The
associations found with the first resistant cultures
were also evident in the supplemented six-month
cultures, but the proportions of cultures with MICs
of 50 µg/ml, as well as those with MICs of 1 and
5 µg/ml, varied according to the treatment regimen
and the rate of inactivation. In the three series
treated with isoniazid alone, cultures with MICs
of 1, 5 or 50 µg/ml were obtained from 56% of the
36 H rapid inactivators, from 38 % of the 45 H slow
inactivators, from 37% of the 27 HI-2 rapid
inactivators and from 21 % of the remaining
105 patients in the HI-2 and HI-1 series, again
demonstrating a decrease in the proportions of
cultures with low, moderate or high degrees of
resistance as the dose of isoniazid was increased.
Cultures with MICs of more than 50 µg/ml were
obtained from 11 % to 19 % of the H patients,
the HI-2 patients and the HI-1 rapid inactivators,
but from only 6% of the HI-1 slow inactivators.
Thus, the differences between the six subgroups of
the isoniazid-alone series in the proportion of
patients who had resistant strains is mainly ac-
counted for by the patients who yielded cultures
of low, moderate or high degrees of resistance,
and not by patients with cultures of very high
resistance.
As with the first resistant culture, the relative
proportion of resistant cultures with different
degrees of resistance within each treatment series
was related to the rate of inactivation of isoniazid.
However, the effect of the rate of inactivation also
occurs in cultures with MICs of 50 µg/ml. Thus,
of the cultures with MICs of 50 µg/ml or less in
the H series, the proportions of cultures with MICs
of 1, 5 and 50 µg/ml were 6 %, 29 % and 65 %,
respectively, of the 17 cultures from slow inactivators,
as compared with 50 %, 35 % and 15 % respectively
of the 20 cultures from rapid inactivators. A
similar trend is evident in the HI-2 series and in
the HI-1 series. Amalgamating the results on
cultures with MICs of 50 µg/ml or less in the three
isoniazid-alone series, cultures with MICs of 1,
5 or 50 µg/ml were obtained from 6 %, 34% and
59%, respectively, of the 32 slow inactivators and
from 35 %, 49% and 16%, respectively, of the 37
rapid inactivators. These differences are highly
significant (P<0.001).
TABLE 6
DEGREE OF RESISTANCE TO ISONIAZID OF THE SUPPLEMENTED SIX-MONTH a CULTURES FROM PATIENTS IN THE FOUR TREATMENT SERIES
Treatment
series
PH
HI-1
HI-2
H
Al l
isoniazid-
alone
series
Rate of Total
inactivation
of isoniazid
patients
(a)
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
Slow
Rapid
All patients
57
26
85b
35
31
67c
38
27
65
45
36
61
118
94
213
Total patients with
supplemented six-
month isoniazid-
resistant cultures
No. % of (a)
5 9
6 23
1 1 13
Minimal inhibitory concentration of isoniazid (µg/ml)
1
No. % of (a)
0 0
3 12
3 4
9 26 0 0
13 42 1 3
22 33 1 2
15 40 1 3
13 48 2 7
28 43 3 5
23 51 1 2
25 69 10 28
46 60 1 1 14
47 40 2 2
5 1 54 13 14
98 46 15 7
5
No. % of (a)
3 5
3 12
6 7
3 9
4 13
7 10
3 8
7 26
10 15
5 11
7 19
12 15
1 1 9
18 19
29 14
a Cultures isolated at either six, seven or five months in this order of preference.
b Indicates the inclusion of two patients whose rate of inactivation of isoniazid was not determined.
c Indicates the inclusion of one patient whose rate of inactivation of isoniazid was not determined.
50 >50
No. % of (a) No. % of (a)
1 2 1 2
0 0 0 0
1 1 1 1
4 11 2 6
2 6 6 19
6 9  8 12
4 10 7 18
1 4 3 11
5 8 10 15
1 1 24 6 13
3 8 5 14
14 17 1 1 14
19 16
6 6  14  15
25 12 29 14
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INFLUENCE OF THE DEGREE OF RESISTANCE TO ISONIAZID
ON THE SUBSEQUENT RESPONSE TO TREATMENT
Of the 136 patients who yielded one or more
isoniazid-resistant cultures, 33 (24 %) attained
bacteriologically quiescent disease at 12 months
(for definition see page 275). Seventeen of these
33 patients had yielded one resistant culture, six
had two resistant cultures, three had three resistant
cultures and seven had four or more resistant
cultures. Since, as shown above, there was a
tendency for the degree of isoniazid-resistance to
increase with continued treatment, it was of particu-
lar interest to determine whether the subsequent
response of the patients to treatment was related
to the degree of resistance of their first resistant
culture or to that of their supplemented six-month
resistant culture.
The degree of resistance of the first resistant
culture and the proportion of patients who yielded
one or more resistant cultures during the year but
nevertheless had bacteriologically quiescent disease
at 12 months are set out in Table 7. Bacteriologi-
cally quiescent disease was attained by 19% of 57 H
patients who had one or more resistant cultures, by
12 % of 33 HI-2 patients, by 30 % of 30 HI-1 patients
and by 56% of 16 PH patients. The difference
between the PH series and the combined isoniazid-
alone series in the proportion of patients with
resistant cultures who had a favourable response is
highly significant (P<0.01). A favourable response
was obtained by 19 (26%) of 72 slow inactivators
and by 14 (23%) of 61 rapid inactivators with
resistant cultures.
Amalgamating the three isoniazid-alone series,
bacteriologically quiescent disease was attained by
22% of the 23 patients with first resistant cultures
that had an MIC of 1 µg/ml, by 20% of 40 with
MICs of 5 µg/ml, by 14% of 28 with MICs of
50 µg/ml and by 24% of 29 with MICs of greater
than 50 µg/ml. Of the 32 slow inactivators who
had first resistant cultures with MICs of 1 or 5 µg/ml,
nine (28 %) attained bacteriologically quiescent
disease as compared with four (14%) of the 29
corresponding rapid inactivators. These differences
do not attain statistical significance. Thus, there
was no clear evidence of an association between the
degree of resistance of the first resistant culture and
the subsequent response of the patients to treatment.
The degree of resistance of the supplemented
six-month resistant cultures and the response to
treatment of the patients who yielded these cultures
is shown in Table 8. There was a suggestion that
patients with isoniazid-resistant cultures more often
had quiescent disease at 12 months in the PH series
(36% of 11 patients) than in the combined isoniazid-
alone series (15 % of 98 patients). With regard to
the degree of resistance of the cultures from patients
treated with isoniazid alone, quiescent disease was
attained by 27 % of 15 patients with cultures having
MICs of 1 µg/ml and by 13 % of 83 patients with
cultures having MICs of 5 µg/ml or more. A
favourable response was obtained by 31% of
13 slow inactivators and by 13 % of 31 rapid
inactivators who had cultures with MICs of 1 or
5 µg/ml. However, none of these differences attains
statistical significance.
In summary, a favourable response to the
allocated regimen of treatment was obtained among
patients who yielded resistant cultures more often
in the PH series than in the series treated with
isoniazid alone. However, no definite association
existed between the degree of resistance and the
further response of the patients treated with
isoniazid alone. There was a slight suggestion that
the response in patients with supplemented six-
month cultures of low degrees of resistance and in
slow inactivators with cultures of low or moderate
degrees of resistance was better than in the remaining
patients.
DISCUSSION
Before relating the degrees of resistance of emerged. There were no appreciable differences
cultures from the patients treated with isoniazid between the times taken for the first resistant
alone to the dosage of isoniazid that they received cultures to appear in the three isoniazid-alone
and to their inactivation status, it was necessary series. Furthermore, the degree of resistance of the
to examine two other factors which might have first resistant cultures was not associated with the
influenced the degree of resistance. The first of month of their emergence. Thus, any differences
these was the duration of treatment before resistance between the four treatment series or between the
TABLE 7
RESPONSE TO TREATMENT RELATED TO THE DEGREE OF RESISTANCE TO ISONIAZID OF THE FIRST RESISTANT CULTURE
Treatment
series
Minimal inhibitory con centration of isoniazid (&ml) All patients with
50 I >50
resistant cultures1
Favourable Favourable
No. of response a No. of response a
patients patients
PH
I 8 IN0
6. % / 6 , N”.  %
HI-I
I 310 li314
HI-2
1513 IQ/l
H / 15 j 2 j 18 j 3
All isoniazid-alone series :
Slow inactivators
I
,6, /
2 (33)  b
I I
-26
Rapid inactivators 3 (19) 1 13 : ::1
Total patients treated
with isoniazid alone
I I
23c 6 (22) 40c 8 20
a Bacteriologically quiescent disease at I2 months.
a The parentheses indicate percentages based on fewer than 25 observations.
6 2 18 13- j50~~~~/~30
9 0 1 10 1 0 ( 33 / 4 12
I3 2 1 57 1 11 19
I7 / 2 (12) / 15 i 3 (20) j 64 / 14 22
10 2 (20) I4 4 (29) ( 63 ( 10 19
28” 4 14 I I29 7 24 I I120 24 20
c including one patient whose rate of inactivation of isoniazid was not determined.
TABLE 8
RESPONSE TO TREATMENT RELATED TO THE DEGREE OF RESISTANCE TO ISONIAZID OF THE SUPPLEMENTED SIX-MONTH RESISTANT CULTURES
Minimal inhibitory concentration of isoniazid (µg/ml) All patients with
5 I 50 >50
resistant cultures
1
Favourable
No. of response a No. of
patients patients
Treatment
series
Rapid inactivators  13  3 (23)  18
Total patients treated
with isoniazid alone 1 5 4 (27) 29
a Bacteriologically quiescent disease at 12 months.
1 6 0 8 3 22 4 (18)
1 5 0 10 0 28 4 14
2 14 3 11 1 48 7 15
3 (27)  19  1 (5)  15  0 (0)  47  5 11
1 (6) 6 2 (33) 14 4 (29) 51 10 20
4 14 25 3 12 29 4 14 98 15 15
b The parentheses indicate percentages based on fewer than 25 observations.
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slow and rapid inactivators in the degree of resistance
of the first resistant cultures could not have been
due to the period of treatment preceding their
emergence. The second factor which might have
influenced the degree of resistance was the severity
of the patient’s disease on admission to treatment.
However, although patients whose initial disease
was more severe yielded resistant cultures with
greater frequency, the degree of resistance of their
cultures was similar to those obtained from patients
with less severe disease. Similar observations were
made by Fox and Sutherland (1955) on patients
treated with isoniazid alone. Furthermore, as can
be seen from Table 15 of the main report of the
present study (Tuberculosis Chemotherapy Centre,
1960) and from further analyses (not tabulated here),
the initial severity of the disease in patients with
resistant cultures was similar in the three treatment
series and in slow and rapid inactivators of isoniazid.
It therefore seems reasonable to regard the differ-
ences between the’ treatment series and between the
slow and rapid inactivators in the degree of
resistance of the first and the supplemented six-month
resistant cultures (cultures at six months, or, when
unobtainable, at five or seven months, see page 219
as having been due only to the dosage of isoniazid
received by the patients and to the rate at which it
was inactivated.
The size of a single dose of isoniazid given in the
three series treated with isoniazid alone ranged from
about 2.2 mg/kg (given twice a day) in the H series,
to 4.4 mg/kg (given twice a day) in the HI-2 series,
and to 8.7 mg/kg (given once a day) in the HI-1
series. Gangadharam et al. (1961 b) measured the
concentrations of isoniazid in the serum of a sample
of the patients in the study and their findings are
summarized in Table 9. The six subgroups, formed
by dividing the patients in each series into rapid or
slow inactivators of isoniazid, could be arranged in
order of increasing peak concentrations, which
ranged from 0.7 µg/ml in the H rapid inactivators
to 6.6 µg/ml in the HI-1 slow inactivators. The
same order was obtained if the six subgroups were
arranged according to the therapeutic response, as
measured by the proportion of patients who had
attained bacteriologically quiescent disease at
12 months. On the other hand, the therapeutic
response in the subgroups was not related to other
measures of the time-serum concentration curves
in the patients and, in particular, it was not related
to the period during a day that inhibitory concen-
trations of isoniazid were present in the serum. It
TABLE 9
PEAK SERUM CONCENTRATIONS
AND BACTERIOLOGICAL CLASSIFICATION
AT 12 MONTHS OF THE PATIENTS IN THE THREE
ISONIAZID-ALONE TREATMENT SERIESa
Treatment
series
HI-1
HI-2
H
Single dose
of isoniazid
(mg/kg)
8.7
4.4
2.2
Slow 6.6 72
Rapid 4.5 66
Slow 2.6 59
Rapid 1.9 56
Slow 1.2 48
Rapid 0.7 44
a From Gangadharam et al. (1961b).
was therefore concluded that the response to
treatment in the six subgroups was determined by
the peak concentration of isoniazid attained.
The present study has shown that the proportion
of patients in the six subgroups who yielded one
or more resistant cultures during the year of treat-
ment decreased as the therapeutic response (and the
peak concentrations) increased. The percentages
were 69% for the H rapid inactivators, 65% for
the H slow inactivators, 52% for the HI-2 rapid
inactivators, 46% for the HI-2 slow inactivators
and 44% for both the rapid and slow inactivators
in the HI-1 series. This progressive decrease in the
proportion of patients with resistant cultures was
accounted for by a corresponding deficit of patients
with first resistant cultures of low or moderate
degrees of resistance; the proportion of patients
whose first resistant cultures were of high or very
high degrees of resistance were similar in the six
subgroups. With the supplemented six-month
resistant cultures the deficits of patients occurred
among those with cultures of low, moderate or
high degrees of resistance, but not in those with
cultures of very high degrees of resistance, presuma-
bly because the supplemented six-month cultures
were usually isolated after the first resistant cultures
and there was evidence that the degree of resistance
increased during treatment. Middlebrook (1952)
and Canetti & Grosset (1961) have shown that
sensitive strains of tubercle bacilli contain isoniazid-
resistant mutants of different degrees of resistance.
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The findings of the present study suggest that in
patients with low peak serum concentrations the
growth of mutants of low or moderate degrees of
resistance occurred more frequently than in those
with higher peak concentrations and that the
differences between the subgroups in the proportion
of patients with resistant cultures was determined
by the ability of these mutants to multiply. Further-
more, the ultimate response of the patients, that
is, whether they attained bacteriologically quiescent
disease, appeared also to be largely dependent on
the initial inhibition of growth of these mutants,
since there was little evidence that the attainment
of quiescent disease after the emergence of resistance
was associated with the degree of resistance of the
first or supplemented six-month resistant cultures.
No evidence was found that a low dosage of
isoniazid, even in rapid inactivators, resulted in
persistent excretion of sensitive organisms, as has
been reported by Russell and Middlebrook (1956)
and by Mitchell and Bell (1957). Indeed, all of the
103 patients whose disease failed to become quiescent
yielded one or more resistant cultures, the excretion
of sensitive cultures in the last six months of treat-
ment occurred rarely and was not associated with
the regimen or the rate of inactivation of isoniazid,
and resistant cultures emerged at similar periods
after the start of treatment in the rapid and slow
inactivators of the three isoniazid-alone series.
Thus, while variation in peak serum concentra-
tions was the factor that seemed to determine the
emergence of bacilli with low degrees of resistance,
there was no reason to believe that the serum
concentrations attained by any patient in the
present study were too low to inhibit sensitive
organisms.
In addition to the association between the
emergence of cultures with low and moderate
degrees of resistance and the peak serum concentra-
tions of isoniazid, a further association was evident,
among the patients from whom a resistant culture
had been obtained, between the degree of resistance
and the rate of inactivation of isoniazid in each of
the treatment series. After amalgamating the
results in the three isoniazid-alone series, first
resistant cultures with low degrees of resistance
were obtained from 19% of the 32 slow inactivators
and from 55% of the 29 rapid inactivators who had
yielded cultures of low or moderate degrees of
resistance. A similar tendency for cultures from
rapid inactivators to be less resistant than cultures
from slow inactivators was also evident in the
supplemented six-month resistant cultures, but, in
keeping with the findings on the emergence of
resistant cultures, the association existed in cultures
with high degrees of resistance as well as in those
with low and moderate degrees.
A possible explanation for the existence of the
two associations considered above is as follows.
Barclay, Koch-Weser & Ebert (1954), Youatt (1958)
and Tsukamura, Tsukamura & Nakano (1963) have
shown that labelled isoniazid is rapidly bound by
isoniazid-sensitive tubercle bacilli, but not by
highly resistant bacilli. On the assumption, sup-
ported by the observations of Tsukamura, Tsu-
kamura & Nakano (1963), that bacilli with fairly
low degrees of resistance also bind isoniazid, it is
suggested that many of these organisms, including
those that are dormant, bind isoniazid and are
inhibited in their growth immediately or fairly soon
after the start of treatment. The extent of binding
would tend towards a maximal value determined
by the peak serum concentration during successive
doses of isoniazid. If the peak concentrations were
low, many of the bacilli with low degrees of resistance
would bind insufficient isoniazid to prevent growth,
but if the peak concentrations were high, these
bacilli would be inhibited and only the more
resistant bacilli could grow, thus accounting for the
negative association between the emergence of
cultures of low or moderate degrees of resistance
and the peak serum concentration. However, among
those resistant bacilli that were able to continue
multiplying, there would be some with relatively
low degrees of resistance whose growth would be
impeded by isoniazid. These organisms would
therefore tend to become more resistant; in the
present study the degree of resistance of resistant
cultures was found to increase slightly during
treatment. In these multiplying organisms there
would be a race between the binding of isoniazid
at available sites and the creation of new sites in
the daughter cells at which binding might occur.
In slow inactivators isoniazid would be present
for longer periods in the lesions and the bacilli
would therefore bind more isoniazid than in rapid
inactivators. Thus, higher degrees of resistance
would be expected in cultures from slow inactivators
than in those from rapid inactivators as long as
the organisms were only partially inhibited by
isoniazid.
In essence, the hypothesis is that there are two
stages in the emergence of isoniazid resistance. In
the first stage, organisms which are sensitive or
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have low degrees of resistance absorb enough
isoniazid to prevent their growth throughout
treatment, while more resistant organisms continue
to grow. The critical degree of resistance separa-
ting organisms that are inhibited and those that
grow is related to the peak serum concentrations
of isoniazid and not to the length of time that
isoniazid is present. In the second stage there is an
increase in the degree of resistance of some of the
organisms that continue to grow. Those with
relatively low, “ border-line ” degrees of resistance
become more resistant (rapidly at first and then
more slowly) as a result of multiple step selection
during growth. Selection for an increase in resistance
is more intense the longer isoniazid is present in the
serum (and in the lesions), so that resistant organisms
within the border-line group become more resistant
in slow inactivators than in rapid inactivators. The
remaining organisms with higher degrees of resist-
ance grow freely and are unaffected by treatment.
The events in the first stage, but not those in the
second stage, determine the outcome of treatment.
The association between the degree of resistance
in border-line cultures (MICs of 1 and 5 µg/ml)
and the inactivation rate of the patient was evident
in the first resistant cultures (Table 5). This finding
implies that the second stage in the emergence of
resistance must have started before these cultures
were obtained. The majority of the first resistant
cultures were obtained during the first four months
of treatment, so that the critical first-stage events–
determining whether or not resistant organisms
multiply at all-must have occurred even earlier.
Thus the eventual response of the patients was
probably decided at a very early stage, perhaps
within a few days or weeks of the start of treatment.
This suggests that in planning chemotherapeutic
regimens particular emphasis must be placed on
giving intensive chemotherapy both with isoniazid,
in at least a moderate dose (400 mg in a single
daily dose), and with other drugs during the early
weeks of treatment to prevent the growth of resistant
mutants. The importance of the early phase of
intensive treatment is supported by the finding of
the Medical Research Council (1962) that the
administration of streptomycin for the first six
weeks increased the efficacy of a regimen of isoniazid
plus PAS in the treatment of pulmonary tuberculosis
with cavitation.
It is evident from the hypothesis that studies
relating the degree of resistance of well-established
resistant cultures to the concentration of isoniazid
in the serum can be misleading in the formulation
of the proper dosage of isoniazid for individual
patients. The second-stage events (which are
irrelevant to therapeutic response) will have already
occurred in these cultures, so that strains from slow
inactivators will have considerably higher degrees
of resistance than those from rapid inactivators.
Since the difference between serum isoniazid
concentrations in slow and rapid inactivators
increases during the period after the dose has been
taken, the best correlation may be found between
the degree of resistance and the serum concentrations
measured later than at the peak, for instance at
three or six hours after the dose. Yet it is the
peak isoniazid concentration (which determines
the first-stage events) that is best related to the
outcome of treatment with isoniazid and should be
used in preference to the three-hour or six-hour
concentration in deciding on dosage.
The influence of the addition of PAS to treatment
with isoniazid can be seen by comparing the
emergence of resistance in the PH and HI-2 patients
whose serum isoniazid concentrations were found
to be similar (Gangadharam et al., 1961b). First,
only 19% of the 85 PH patients yielded a resistant
culture, as compared with 49% of the 67 HI-2
patients. Secondly, resistant cultures were obtained
during the first four months of treatment from 25 %
of the PH patients and from 85 % of the HI-2 patients
who yielded resistant cultures at any time during
the 12 months of treatment. Thus, the concomitant
administration of PAS prevented the emergence of
resistance in a considerable proportion of the
patients and, in those who yielded resistant cultures,
their emergence was delayed. A further difference
between the series was that low or moderate degrees
of resistance were found in 88 % of the first resistant
cultures in the PH series, but in only 42% of the
corresponding cultures in the HI-2 series. The
supplemented six-month cultures also had lower
degrees of resistance in the PH series than in the
HI-2 series. An explanation for these differences is
that PAS either inhibited the growth of isoniazid-
resistant mutants completely or, if growth occurred,
slowed it down considerably, thus accounting for
the delay in the emergence of resistance. If it is
accepted that growth of border-line resistant
organisms during treatment resulted in an increase
of the degree of their resistance, then slowing down
of their growth by PAS would also lead to a lower
degree of resistance than if isoniazid were used alone.
The preponderance of cultures with low or moderate
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degrees of resistance to isoniazid in patients treated
with isoniazid plus PAS is consistent with the
finding of Nassau & Hamilton (1955) that cultures
resistant to isoniazid and PAS were more frequently
cat&se-positive than were cultures resistant only
to isoniazid.
From 6% to 13 % of the patients in the four
treatment series yielded one or more isoniazid-
resistant cultures but nevertheless attained bacterio-
logically quiescent disease by 12 months. It must
be noted that although the percentage of patients
who yielded resistant cultures but subsequently
attained bacteriological quiescence was low, this
percentage nevertheless represented more than half
of the patients in the PH series who excreted one
or more isoniazid-resistant cultures. Thus, the
prognostic significance of the emergence of an
isoniazid-resistant culture in patients treated with
isoniazid plus PAS is not as serious as in patients
treated with isoniazid alone.
SUMMARY
1. The results are reported of isoniazid sensitivity
tests on cultures obtained at monthly intervals
from 305 South Indian patients with pulmonary
tuberculosis who participated in a comparison of
four regimens of domiciliary chemotherapy. The
regimens (and the dosages appropriate to patients
weighing 100 lb. (45.4 kg)) were: (a) PH–200 mg
of isoniazid plus 10 g of PAS (sodium) a day,
divided into two doses; (b) HI-1–400 mg of iso-
niazid a day, in one dose; (c) HI-2–400 mg of
isoniazid a day, divided into two doses; (d) H–
200 mg of isoniazid a day, divided into two doses.
The dosage of each regimen was graded according
to the patient’s weight. None of the patients had
had more than two weeks of previous chemotherapy,
and all had isoniazid-sensitive organisms on admis-
sion to treatment. They were classified as slow or
rapid inactivors of isoniazid.
2. The degree of resistance was measured as the
minimal concentration of isoniazid that prevented
the growth of 20 or more colonies after inoculation
of approximately 105 viable units. The degree of
resistance was reasonably reproducible in duplicate
tests on the same culture and in tests on cultures
obtained at six months and at seven months from
the same patient.
3. All of the 103 patients who failed to attain
bacteriologically quiescent disease at 12 months
yielded resistant cultures. In the second six months
of treatment, only nine of 415 cultures tested were
isoniazid-sensitive and the finding of a sensitive
culture was not associated with the dosage of
isoniazid or with the rate of its inactivation. The
serum concentrations of isoniazid attained by any
patient did not, therefore, appear to be too low to
inhibit sensitive organisms.
4. The three isoniazid-alone series were similar
in the month in which the first resistant culture
emerged; 80% of the resistant cultures emerged
during the first four months of treatment. The
degree of resistance of the first resistant cultures
was not associated with the month in which it
emerged.
5. There was a slight increase in the degree of
resistance of resistant cultures as treatment was
continued.
6. The degrees of resistance of the first resistant
cultures and of the “ supplemented six-month ”
resistant cultures (comprising a culture obtained
from each patient at six months, or, if not available
or negative, at seven or five months) were not
associated with the extent of cavitation, the total
extent of disease or the bacterial content of the
sputum of the patients on admission to treatment.
7. The proportion of patients with resistant
cultures in the six sub-groups, formed by dividing
each of the isoniazid-alone series into rapid and
slow inactivators, ranged from 69% in the H rapid
inactivators, to 65% in the H slow inactivators,
to 52% in the HI-2 rapid inactivators, to 46 % in
the HI-2 slow inactivators and to 44% in the
HI-1 rapid and slow inactivators. The corresponding
percentages of those who yielded supplemented
six-month resistant cultures were 69 %, 51%, 48 %,
40%, 42% and 26%, respectively. The progressive
decrease in the proportion of patients with resistant
cultures was mainly due to corresponding deficiencies
of patients who yielded first resistant cultures with
low or moderate degrees of resistance or sup-
plemented six-month cultures with low, moderate
or high degrees of resistance; the proportion of
patients with cultures of higher degrees of resistance
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remained fairly constant in each subgroup. Since
the order of these subgroups arranged according
to the proportion of patients yielding resistant
cultures is the same as the order arranged according
to the peak concentrations of isoniazid obtained in
the serum during treatment, it seems that the early
growth of resistant mutants with relatively low
degrees of resistance and, therefore, the proportion
of patients who yielded resistant cultures were
dependent on the peak serum concentrations
attained.
8. In the eight subgroups of rapid and slow
inactivators in the four treatment series, failure to
respond to treatment, as assessed by the proportion
of patients who did not attain bacteriologically
quiescent disease at 12 months, was closely associ-
ated with the proportion of patients who yielded
first or supplemented six-month resistant cultures.
However, there was no definite association between
the degree of resistance of these resistant cultures
and the subsequent response to treatment. Thus,
the ultimate response of the patients appeared to
depend on the ability of resistant mutants to
multiply in the early stages of treatment.
9. A further association existed between the
degree of resistance of resistant cultures that had
emerged and the rate of inactivation of isoniazid.
Of first resistant cultures with low or moderate
degrees of resistance, cultures with low degrees of
resistance were obtained from 19% of 32 slow
inactivators and from 55 % of 29 rapid inactivators.
A similar association existed among six-month
supplemented cultures. It is suggested that the
higher degree of resistance in slow inactivators is
due to partial inhibition of multiplying resistant
bacilli by the prolonged presence of low concentra-
tions of isoniazid and consequent selection of more
highly resistant organisms.
10. Resistant cultures were obtained from 19 % of
the 85 PH patients and from 49% of the 67 HI-2
patients (similar serum isoniazid concentrations
were found in the two series) during treatment.
The first resistant culture was obtained during the
first four months in 25 % of the 16 PH patients and
in 85 % of the 33 HI-2 patients who yielded resistant
cultures; low or moderate degrees of resistance
were found in 88% of the PH cultures and in
42% of the HI-2 cultures. Thus, the concomitant
administration of PAS frequently prevented the
emergence of resistance, and, in those who yielded
resistant cultures, its emergence was delayed and
the degree of resistance was low.
11. It is concluded that the response to 12 months’
treatment depends largely on whether mutants with
low degrees of resistance are able to multiply in
the very early stages of treatment. Since the growth
of these mutants is prevented by high peak concen-
trations of isoniazid, it is suggested that intensive
chemotherapy should be given at the start of
treatment.
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RÉSUMÉ
Les auteurs exposent les résultats du test de sensibilite
à l’isoniazide, appliqué tous les mois aux bacilles tuber-
culeux provenant de 305 sujets de 1’Inde méridionale,
atteints de tuberculose pulmonaire, et soumis, par
groupes, à quatre regimes thérapeutiques à domicile, qui,
pour des malades pesant environ 45 kg étaient les
suivants: série PH: 200 mg d’isoniazide + 10 g par jour
de PAS (sel sodique), en deux doses; série HI-1 : 400 mg
d’isoniazide par jour, en deux doses; série H-2: 400 mg
d’isoniazide par jour, en deux doses; série H: 200 mg
d’isoniazide par jour, en deux doses. Les doses étaient
adaptées au poids de chaque malade. Aucun des sujets
n’avait eu, auparavant, plus de deux semaines de chimio-
thérapie, et au commencement du traitement, tous les
bacilles étaient sensibles à l’isoniazide. Les malades
furent classés en inactivateurs rapides et inactivateurs
lents.
Le degré de resistance a été évalué d’après la concen-
tration minimum d’isoniazide inhibant le développement
au point de ne permettre la croissance que de 20 colonies
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au maximum, à partir d’un inoculum de 105 bacilles.
Le degré de résistance était le même, à une approximation
satisfaisante, dans les tests répétés avec la même culture
ou les tests effectués 6 ou 7 mois après sur les mêmes
malades.
Les 103 malades qui n’atteignirent pas le stade de
quiescence bactériologique après 12 mois, présentaient
des bacilles résistants. Dans les 6 derniers mois du
traitement, 9 seulement des 415 cultures soumises au test
étaient sensibles à l’isoniazide, et aucune relation n’a pu
être établie entre la résistance et la quantité d’isoniazide
du régime thérapeutique ou la vitesse d’inactivation. La
concentration du sérum en isoniazide, atteinte par chaque
malade, ne paraissait donc pas trop faible pour inhiber
les bacilles sensibles.
Le mois où apparurent les premieres cultures r&is-
tantes, les trois séries comportant de l’isoniazide seule-
ment se comportaient de façon analogue; 80% des
cultures résistantes apparurent durant les 4 premiers
mois de traitement. Le degré de résistance des premieres
cultures résistantes n’était pas en relation avec le mois de
leur apparition.
On constata une légère augmentation de la résistance
chez les cultures résistantes au fur et à mesure que le
traitement progressait.
Le degré de résistance des premieres cultures résistantes
et des cultures supplémentaires (une culture provenant
de chaque malade après 6 mois de traitement – ou
éventuellement 5 ou 7 mois) n’était en relation ni avec
l’étendue des cavités, ni avec celle de la maladie en
général, ni avec la teneur en bacilles des crachats, au
moment de l’admission des malades.
La proportion de malades présentant des cultures
résistantes, dans les six sous-groupes formés en répar-
tissant chacun des groupes ne recevant que de l’isoniazide
en inactivateurs rapides et inactivateurs lents, s’éche-
lonnait entre les limites suivantes: série H, 69% chez les
rapides à 65 % chez les lents ; série HI-2, 52 % chez les ra-
pides à 46 % chez les lents; série HI-1, 44 % dans les deux
groupes. Les proportions correspondantes des malades
des groupes ci-dessus donnant des cultures résistantes
à 6 mois étaient 69 %, 51%, 48 %, 42 %, et 26 % respec-
tivement. Cette proportion décroissante de malades
présentant des cultures résistantes étant en rapport avec
le maximum de la teneur du sérum en isoniazide, il
semble que la proportion de malades donnant des
cultures résistantes dépende de ce facteur.
Dans les 8 sous-groupes (inactivateurs rapides et lents)
des 4 séries de traitement, l’échec du traitement – évalué
par la proportion de malades n’ayant pas atteint le
stade de quiescence bactériologique en 12 mois –, était
en rapport étroit avec la proportion de malades présentant
des cultures résistantes. Cependant, il n’y avait pas de
rapport net entre le degré de résistance des cultures et
la réponse subséquente au traitement. Il semble que,
finalement, la réponse des malades dépende de la faculté
des mutants résistants de se multiplier au cours des
premiers stades du traitement.
On a constaté une relation entre le degré de résistance
des cultures et le taux d’inactivation de l’isoniazide.
On a obtenu, parmi les premières cultures résistantes,
des cultures présentant un faible degré de résistance
chez 19 % de 32 inactivateurs lents, et 55 % de 29 inactiva-
teurs rapides. Il en était de même pour les cultures pré-
levées à 6 mois. On peut penser que le degré plus élevé
de résistance chez les inactivateurs lents est dû à l’inhi-
bition partielle de la multiplication des bacilles résistants
par la présence, durant des périodes prolongées, de faibles
concentrations sériques d’isoniazide, et la sélection
d’organismes plus résistants qui s’ensuivit.
L’expérience a montré également que l’administration
de PAS avec l’isoniazide permettait d’éviter ou de
retarder l’apparition de la résistance, et d’atténuer le
degré de la résistance manifestée par les bacilles.
Les auteurs concluent que le résultat d’une chimio-
thérapie de 12 mois dépend en grande partie de la
possibilité pour les mutants résistants de se multiplier
durant les premiers stades du traitement. Puisque
l’expérience montre que leur croissance est inhibée par
des taux élevés d’isoniazide sérique, ils estiment qu’une
chimiothérapie intensive devrait être administrée au
début du traitement.
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